Dr. Scott M. Rocklage holds a Ph.D. degree. In 2003, he joined 5 AM Ventures. He was a Venture Partner then. After a year he became its Managing Partner.
Dr. Scott M. Rocklage has worked in healthcare management for over three decades. His strategic leadership skills have led to FDA approving three U.S. New Drug Applications. These are namely Omniscan™, Teslascan® besides Cubicin®.
He has been the Chairman as well as CEO of Cubist Pharmaceuticals. Dr. Scott M. Rocklage has also served as the President and CEO of Nycomed Salutar. He held R&D positions at Salutar and Catalytica. Earlier, Dr. Scott M. Rocklage was the Board Chairman of Relypsa besides Novira, which has been acquired by J&J.
Currently, he is the Board Chairman of Rennovia, Kinestral, and Cidara. He is also on the Boards of Epirus as well as Pulmatrix.
Dr. Scott M. Rocklage has held many prominent positions earlier. He was formerly the Executive Chairman of Ilypsa, Miikana besides Semprus.
Dr. Scott M. Rocklage has completed his B.S. in Chemistry. This was from the University of California, Berkeley. He did his Ph.D. in Chemistry from MIT. Here he was doing research in the laboratory of Richard R. Schrock.
Dr. Scott M. Rocklage is well-known for being an inventor or a co-inventor of more than 30 U.S. patents. He is also known for over 100 peer-reviewed publications. He is working from the Boston, MA office.
5 AM Ventures is a seed and early-stage venture capital firm. It is involved in creating as well as building various biotechnology companies. Dr. Scott M. Rocklage had joined its team of three investment professionals, namely John Diekman, Andy Schwab as well as Carin Mueller. These people had founded 5 AM Ventures in 2002. It was created out of Bay City Capital in June 2002. 5 AM Ventures started out by making investments in six biotechnology companies that included Alexza, Ambrx, besides Celscia Therapeutics, Kalypsys as well as Miikana Therapeutics and Symyx Therapeutics.
Dr. Scott M. Rocklage was an addition to this investment team. He was able to establish strong development pipelines. In addition, he was able to build infrastructure to facilitate drug launches.